Archives
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
Reliable Lipid Peroxidation (MDA) Assay Kit for Reproducible
2026-07-14
This article explores real-world laboratory challenges in quantifying lipid peroxidation, detailing how the Lipid Peroxidation (MDA) Assay Kit (SKU K2167) addresses issues of reproducibility, sensitivity, and workflow safety. Drawing on evidence from oxidative stress and ferroptosis research, it establishes the kit as a benchmark for malondialdehyde (MDA) measurement in cell and tissue models. Examples highlight validated protocols, practical troubleshooting, and vendor considerations for biomedical labs.
-
CCCP in Translational Mitochondrial Biomarker Discovery
2026-07-14
This thought-leadership article explores CCCP (carbonyl cyanide m-chlorophenyl hydrazine) as a strategic tool for translational researchers investigating mitochondrial dysfunction, with a central focus on non-invasive biomarker development in Alzheimer’s disease. By integrating mechanistic insight, evidence from deep learning-enabled urine stem cell analysis, and practical guidance, the article positions CCCP as indispensable for next-generation functional assays, and offers protocol recommendations and a vision for future research.
-
Molidustat (BAY85-3934): Streamlining HIF-PH Inhibition Work
2026-07-13
Molidustat (BAY85-3934) empowers renal anemia research with precise HIF pathway modulation and reproducible erythropoietin stimulation. This guide details hands-on protocol optimization, troubleshooting, and translational opportunities, leveraging both primary evidence and cross-study insights.
-
LAMP1 Controls CXCL10-CXCR3 Axis in Macrophage Polarization
2026-07-13
This study reveals how LAMP1 modulates macrophage polarization through the CXCL10-CXCR3 axis, with distinct roles in inflammatory and non-inflammatory contexts. The findings highlight differential effects of CXCR3 antagonism and identify LAMP1 as a molecular switch, informing future research on immune regulation and inflammation.
-
Optimizing Cancer Research with YC-1 (5-(1-benzyl-1H-indazol
2026-07-12
YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol stands out as a dual-pathway modulator for dissecting hypoxia and cGMP signaling in advanced cancer research. Discover how its unique properties enable precise inhibition of HIF-1α and tumor angiogenesis, with workflow-ready guidance for troubleshooting and assay optimization.
-
Coumestrol: Phytoestrogen Estrogen Receptor Antagonist for R
2026-07-10
Coumestrol, supplied by APExBIO, empowers advanced studies targeting fibroblast-like synoviocytes in rheumatoid arthritis. Its dual function as a phytoestrogen and potent estrogen receptor antagonist enables precise modulation of nuclear signaling and ferroptosis, with robust workflow optimizations for reproducible results.
-
EZH2 Suppresses Mesenchymal Genes in Breast Carcinoma Cells
2026-07-09
Gallardo et al. reveal that EZH2, via PRC2, directly represses mesenchymal gene expression, maintaining the epithelial phenotype in breast carcinoma cells. Their findings provide mechanistic insights into cancer cell plasticity and suggest that targeting EZH2 could impact epithelial-mesenchymal transition (EMT) in breast and other carcinomas.
-
Nutlin-3a MDM2 Inhibitor: Advanced Workflows for Cancer Rese
2026-07-09
Nutlin-3a empowers translational cancer research with precise, reproducible p53 pathway activation and apoptosis induction. This article delivers protocol enhancements, real-world troubleshooting, and actionable insights for advanced applications, including glioblastoma models and beyond.
-
RNAi Screen Reveals Vesicular Transport in SARS-CoV-2 Egress
2026-07-08
Kerr et al. performed an arrayed RNA interference screen targeting the druggable genome in human cells to identify host factors essential for the full SARS-CoV-2 replication cycle. Their work uncovers key vesicular transport proteins involved in viral release and demonstrates that cyclin-dependent kinase 9 (CDK9) inhibition impedes virus egress, suggesting new avenues for host-directed antiviral strategies.
-
Sulfo-NHS-SS-Biotin: Precision Tools for Translational Prote
2026-07-08
A thought-leadership exploration of Sulfo-NHS-SS-Biotin's mechanistic advantages, strategic relevance, and practical impact for translational researchers interrogating proteostasis, with a focus on cell surface protein labeling and affinity purification workflows.
-
Latrunculin A: Practical Solutions for Cytoskeleton Disaggre
2026-07-07
This article provides scenario-driven guidance for biomedical researchers using Latrunculin A (SKU B7555) to achieve robust, reproducible actin cytoskeleton disruption in cell viability and cytotoxicity assays. Grounded in peer-reviewed data and product-specific insights, it clarifies best practices, protocol parameters, and vendor selection to optimize actin-targeted experiments.
-
Humanized Mice Reveal Species Differences in Ester Prodrug P
2026-07-07
This study demonstrates that humanized mice provide an accurate in vivo-in vitro correlation for the metabolism of the ester prodrug HD56, highlighting significant species-specific differences in pharmacokinetics. The findings offer a robust translational bridge for optimizing prodrug development and predicting human drug metabolism.
-
Ruxolitinib (INCB018424): Applied Protocols in Myeloprolifer
2026-07-06
Ruxolitinib (INCB018424) empowers myeloproliferative disorder research with highly selective JAK1/2 inhibition and robust immune modulation workflows. This guide translates bench protocols and troubleshooting insights for reproducible, high-resolution studies using APExBIO's trusted compound.
-
ML216 and BLM Helicase: Advancing Synthetic Lethality in Can
2026-07-06
Explore how ML216, a potent BLM helicase inhibitor, empowers translational researchers to harness synthetic lethality in DNA repair-deficient cancers. This article bridges mechanistic insight, actionable protocol guidance, and strategic outlook, underscoring the translational promise of targeting BLM and allied RecQ helicases with high-selectivity small molecules.
-
PAD4-IN-2 TFA: Mechanistic Insights & Immune Modulation in T
2026-07-05
Discover how PAD4-IN-2 TFA (Compound 5i TFA) offers unprecedented tumor selectivity and immune microenvironment modulation through precise inhibition of histone H3 citrullination and NET formation. This article uncovers mechanistic breakthroughs and practical implications for advanced cancer research.